Universal use of inactivated polio vaccine

Jornal de Pediatria

Volumn 82, Issue SUPPL. 1, 2006, Pages

  Carvalho, Luiza Helena Falleiros ^a,b,c,d,h   Weckx, Lily Yin ^e,f,g  

^a FACULDADE DE MEDICINA DE MARÍLIA   (Brazil)

^b UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^c Sociedade Brasileira de Pediatria (SBP)   (Brazil)

^d INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIFESP EPM ^*  (Brazil)

^g Secretaria da Saude do Estado de Sao Paulo   (Brazil)

^h Saúde do Estado de São Paulo ^*  (Brazil)

Author keywords

Eradication of polio; IPV vaccine; OPV vaccine; Polio epidemic; Poliomyelitis; World Health Organization

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE;

DRUG EFFICACY; DRUG MANUFACTURE; HERD IMMUNITY; HUMAN; IMMUNOGENICITY; PARALYSIS; POLIOMYELITIS; PRACTICE GUIDELINE; PREVALENCE; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VIRUS MUTATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

HUMANS; IMMUNIZATION PROGRAMS; MUTATION; PAN AMERICAN HEALTH ORGANIZATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; POPULATION SURVEILLANCE; VIRUS REPLICATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 33750501592     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1493     Document Type: Review

References (52)

1. World Health Organization. Global Polio Initiative - Monovalent oral polio vaccines - Fact Sheet 2005. http://www.polioeradication.org/factsheets. asp. Access: 18/04/06.
2. Smith J, Leke R, Adams A, Tangermann RH. Certification of polio eradication: process and lessons learned. Bull World Health Organ. 2004;82:24-30.
3. World Health Organization, Centers for Disease Control and Prevention, United Nations Children's Fund. Global Polio Eradication Initiative - The history. http://www.polioeradication.org/history.asp. Access: 18/04/06.
4. World Health Organization, Regional Office for South East Asia. Immunization and vaccine development polio eradication. 2005. http://w3.whosea.org/EN/Section1226/Section1228.htm. Access: 18/04/06.
5. World Health Organization, Centers for Disease Control and Prevention, United Nations Children's Fund. Polio eradication in India. http://www. polioeradication.org/content/videoaudio/diary/index.asp. Access: 18/04/06.
6. World Health Organization, Centers for Disease Control and Prevention, United Nations Children's Fund. Global Polio Eradication Initiative - Strategic plan 2004-2008. http://www.polioeradication.org/content/publications/ 2004stratplan.pdf. Access: 18/04/06.
7. World Health Organization, Centers for Disease Control and Prevention, United Nations Children's Fund. Now, more than ever, stop polio forever. Polio Situation Report. 2005 Oct. http://www.polioeradication.org/content/general/ PolioSitRepOctober2005ENG.pdf. Access: 18/04/06.
8. World Health Organization, Centers for Disease Control and Prevention, United Nations Children's Fund. Global Polio Eradication Initiative - Global case count 2005. http://www.polioeradication.org/casecount.asp. Access: 18/04/06.
9. World Health Organization. New tools move polio eradication drive into final stage. Technical body highlights Nigeria as single greatest risk to polio-free world. 2005. http://www.who.int/mediacentre/news/releases/2005/pr49/ en/. Access: 18/04/06.
10. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. Formaldehyde and safety testing of experimental poliomyelitis vaccines. Am J Public Health. 1954;44:563-70.
11. Nathanson N, Langmuir A. The cutter incident. Poliomyelitis following formaldehyde - inactivated poliovirus vaccination in the United States during the spring of 1955. Am J Hyg. 1963;78:16-81.
12. Salk D, van Wezel AL, Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infection vaccine. Lancet. 1984;2:1317-21.
13. Simões EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child. 1985;139:977-80.
14. Zhaori G, Sun M, Ogra PL. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J Infect Dis. 1988;158:160-5.
15. Selvakumar R, John TJ. Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine. 1987;5:141-4.
16. Centers for Disease Control and Prevention. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine - supplementary statement. MMWR Morb Mortal Wkly Rep. 1987;36:795-8.
17. Plotkin S, Vidor E. Poliovirus vaccine - inactivated. In: Plotkin S, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: Elsevier; 2004. p. 625-49.
18. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc. 1957;164:1216-23.
19. Fox JP. Modos de acción de las vacunas antipoliomielíticas en relación con la inmunidad resultante. In: Simposio Internacional sobre el Control de la Poliomielitis. Washington: Organización Panamericana de la Salud; 1985. p. 77-82. (Publicación Científica, 484).
20. Ogra PL, Karzon DT, Righthand F, MacGillivray M. Immunoglobulin response in serum and secretions after immunization with live and inactivated polio vaccine and natural infection. New Engl J Med. 1968;279:893-900.
21. John JT, Pandian R, Gadomski A, Steinhoff M, John M, Ray M. Control of poliomyelitis by pulse immunisation in Vellore, India. Br Med J (Clin Res Ed). 1983;286:31-2.
22. Heymann DL, Murphy K, Brigaud M, Aymard M, Tembon A, Maben GK. Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates. Bull World Health Organ. 1987;65:495-501.
23. American Academy of Pediatrics. Poliovirus infections. In: Pickering LK, editor. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village: American Academy of Pediatrics; 2003. p. 505-9.
24. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of the viral interference. Am J Epidemiol. 1972;96:263-9.
25. Swartz TA, Skalska P, Gerichter CG, Cockburn WC. Routine administration of oral polio vaccine in a subtropical area. Factors possibly influencing seroconversion rates. J Hyg (Lond). 1972;70:719-26.
26. John TJ. Antibody response of infants in tropics to five doses of oral polio vaccine. Br Med J. 1976;1:812.
27. Sutter RW, Kew OM, Cochi SL. Live attenuated poliovirus vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders; 2004. p. 651-705.
28. Sokhey J, Gupta CK, Sharma B, Singh H. Stability of oral polio vaccine at different temperatures. Vaccine. 1988;6:12-3.
29. Dömok I, Balayan MS, Fayinka OA, Skrtic N, Soneji AD, Harland PS. Factors affecting the efficacy of live poliovirus vaccine in warm climates. Bull World Health Organ. 1974;51:333-47.
30. Samoilovich E, Roivanen M, Titov LP, Hovi T. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol. 2003;71:274-80.
31. Chin TD. Immunity induced by inactivated poliovirus vaccine and excretion of virus. Rev Infect Dis. 1984;6 Suppl 2:S369-70.
32. Schaap GJ, Bijkerk H, Coutinho RA, Kapsenberg JG, van Wezel AL. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol. 1984;29:124-40.
33. Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med. 1994;11:426,429-30,435-8.
34. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-25.
35. Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde. Dados informativos e estatísticos do SI-EAPV. Eventos adversos pós-vacinais. http://pni.datasus.gov.br/controle_arq_eapv_2005. asp. Access: 18/04/06.
36. a ed. Brasília: FUNASA; 2002. p. 653-70.
37. Centers for Disease Control and Prevention. Laboratory surveillance for wild poliovirus and vaccine-derived poliovirus, 2000-2001. MMWR Morb Mortal Wkly Rep. 2002;51:369-71.
38. Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ. 2004;82:16-23.
39. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635.
40. Minor PD, Almond JW. Poliovirus vaccines: molecular biology and immune response. In: Semler BL, Winner E, editors. Molecular biology of picornaviruses. Washington: ASM Press; 2002. p. 381-90.
41. Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, et al. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol. 2000;74:8434-43.
42. Minor PD. The molecular biology of poliovaccines. J Gen Virol. 1992;73:3065-77.
43. World Health Organization, Regional Committee. Polioeradication: final strategy. In: 10th Meeting of Health Secretaries of Countries of the SEA Region (SEA/HSM/Meet10/5); 2005 July 18.
44. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J , Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356-9.
45. Centers for Disease Control and Prevention. Poliovirus infections in four unvaccinated children, Minnesota, August - October 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1053-5.
46. Labadie K, Pelletier I, Saulnier A, Martin J, Colbère Garapin F. Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology. 2004;318:66-78.
47. Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, Halmut T, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol. 2000;38:3729-34.
48. World Health Organization. Gates Foundation funds new polio vaccine to accelerate eradication efforts Monovalent Oral Polio Vaccine destined for Egypt, bringing faster child immunity against predominant polio strain. 2005. http://www.who.int/mediacentre/news/notes/2005/np03/en/. Access: 18/04/06.
49. Andre FE. Strengths and weaknesses of current polio vaccines - a view from industry. Dev Biol (Basel). 2001;105:61-6.
50. Sangrujee N, Caceres VM, Cochi SL. Cost analysis of post polio certification immunization policies. Bull World Health Organ. 2004;82:9-15.
51. World Health Organization. Polio News. 2005;24. http://www. polioeradication.org/content/polionews/PolioNews24.pdf. Access: 18/04/06.
52. World Health Organization. Framework for national policy makers in OPV-using countries - Cessation of routine OPV use after global polio eradication - 2005. http://www.polioeradication.org/content/publications/ OPVCessationFrameworkEnglish.pdf. Access: 18/04/06.